[{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"fe022431-48d1-445d-8c8d-2321aa360be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828082","created_at":"2023-04-25T14:03:34.885Z","updated_at":"2024-07-02T16:34:26.664Z","phase":"Phase 2","brief_title":"Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer","source_id_and_acronym":"NCT05828082","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SPOP • RAC1 • FDFT1 • MVD","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP • RAC1 • FDFT1 • MVD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/16/2023","start_date":" 10/16/2023","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 04/25/2025","study_completion_date":" 04/25/2025","last_update_posted":"2024-06-12"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"},{"id":"b5e16538-f022-4496-bc0f-845df258feb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01942837","created_at":"2021-01-18T08:47:53.085Z","updated_at":"2024-07-02T16:36:01.969Z","phase":"Phase 2","brief_title":"Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT01942837","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" SPOP","pipe":" | ","alterations":" AR mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/13/2013","start_date":" 09/13/2013","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2022-10-24"},{"id":"c9290568-594d-4db4-8dee-d6569ecbe250","acronym":"ARNEO","url":"https://clinicaltrials.gov/study/NCT03080116","created_at":"2021-01-18T15:10:23.112Z","updated_at":"2024-07-02T16:36:36.870Z","phase":"Phase 2","brief_title":"Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy","source_id_and_acronym":"NCT03080116 - ARNEO","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" PTEN • FOLH1 • SPOP","pipe":" | ","alterations":" FOLH1 expression","tags":["PTEN • FOLH1 • SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-12-24"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"6b8bf719-5c1e-4c86-a97f-384cf98014e4","acronym":"CHRU-WCMC","url":"https://clinicaltrials.gov/study/NCT03421015","created_at":"2021-01-18T16:52:39.017Z","updated_at":"2024-07-02T16:36:53.886Z","phase":"","brief_title":"Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution","source_id_and_acronym":"NCT03421015 - CHRU-WCMC","lead_sponsor":"University Hospital, Lille","biomarkers":" TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1","pipe":" | ","alterations":" TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion","tags":["TP53 • PIK3CA • PTEN • ERG • SPOP • TMPRSS2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PIK3CA mutation • PTEN mutation • TMPRSS2-ERG fusion"],"overall_status":"Unknown status","enrollment":" Enrollment 84","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2019-11-07"},{"id":"726d61ed-f804-458a-b056-93397dea9cac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03677414","created_at":"2022-06-12T22:54:48.968Z","updated_at":"2024-07-02T16:37:06.744Z","phase":"","brief_title":"Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer","source_id_and_acronym":"NCT03677414","lead_sponsor":"Medical University of Graz","biomarkers":" EGFR • TP53 • PIK3CA • BRCA1 • PTEN • HRAS • RB1 • NRG1 • CTNNB1 • PIK3CB • SPOP • ZFHX3 • GRIN2A","pipe":" | ","alterations":" MLL3 mutation","tags":["EGFR • TP53 • PIK3CA • BRCA1 • PTEN • HRAS • RB1 • NRG1 • CTNNB1 • PIK3CB • SPOP • ZFHX3 • GRIN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL3 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 59","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 08/31/2021","study_completion_date":" 08/31/2021","last_update_posted":"2018-09-19"}]